India, Sept. 27 -- Eli Lilly and Company (LLY) announced that the U.S. Food and Drug Administration approved Olumiant (baricitinib) for the treatment of severe alopecia areata in pediatric patients aged 12 years and older, extending the medicine's use beyond adults.
The approval broadens Olumiant's U.S. label and adds to its existing indications, which include treatment of adults with severe alopecia areata and moderately to severely active rheumatoid arthritis.
Alopecia areata is a chronic immune-mediated disorder that causes unpredictable hair loss and can significantly affect patients' quality of life.
The FDA's decision was supported by results from BRAVE-AA-PEDS, the first and largest Phase 3 clinical trial designed specifically to ...